Guanfacine monotherapy for ADHD/ASD comorbid with Tourette syndrome: a case report.
Atomoxetine
Attention deficit/hyperactivity disorder
Autism spectrum disorder
Guanfacine
Methylphenidate
Tourette syndrome
Journal
Annals of general psychiatry
ISSN: 1744-859X
Titre abrégé: Ann Gen Psychiatry
Pays: England
ID NLM: 101236515
Informations de publication
Date de publication:
2019
2019
Historique:
received:
10
11
2018
accepted:
20
02
2019
entrez:
23
3
2019
pubmed:
23
3
2019
medline:
23
3
2019
Statut:
epublish
Résumé
Patients with attention deficit/hyperactivity disorder (ADHD) often experience comorbid conditions, such as autism spectrum disorder (ASD) and Tourette syndrome (TS). Although pharmacotherapies are effective for treating ADHD, they are likely to elicit a variety of adverse effects. It is, thus, important to select an effective and well-tolerated pharmacotherapeutic treatment for patients with ADHD/ASD comorbid with TS. We report the case of a 10-year-old boy with ADHD/ASD comorbid with TS who was treated with guanfacine (GUAN). He experienced several side effects of atomoxetine (ATX) and methylphenidate (MPH) before being treated with GUAN. In the presented case, symptoms of ADHD as well as tic symptoms were improved by treatment with GUAN. GUAN might be effective and well tolerated in the treatment of patients with ADHD/ASD comorbid with TS who experience side effects of ATX and MPH.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with attention deficit/hyperactivity disorder (ADHD) often experience comorbid conditions, such as autism spectrum disorder (ASD) and Tourette syndrome (TS). Although pharmacotherapies are effective for treating ADHD, they are likely to elicit a variety of adverse effects. It is, thus, important to select an effective and well-tolerated pharmacotherapeutic treatment for patients with ADHD/ASD comorbid with TS.
CASE PRESENTATION
METHODS
We report the case of a 10-year-old boy with ADHD/ASD comorbid with TS who was treated with guanfacine (GUAN). He experienced several side effects of atomoxetine (ATX) and methylphenidate (MPH) before being treated with GUAN. In the presented case, symptoms of ADHD as well as tic symptoms were improved by treatment with GUAN.
CONCLUSION
CONCLUSIONS
GUAN might be effective and well tolerated in the treatment of patients with ADHD/ASD comorbid with TS who experience side effects of ATX and MPH.
Identifiants
pubmed: 30899317
doi: 10.1186/s12991-019-0226-6
pii: 226
pmc: PMC6410501
doi:
Types de publication
Case Reports
Langues
eng
Pagination
2Références
Child Adolesc Psychiatr Clin N Am. 2000 Jul;9(3):541-55, vii
pubmed: 10944656
Am J Psychiatry. 2001 Jul;158(7):1067-74
pubmed: 11431228
Mol Psychiatry. 2001 Nov;6(6):657-64
pubmed: 11673793
J Neurosci. 2002 Oct 1;22(19):8771-7
pubmed: 12351753
Neuropsychopharmacology. 2002 Nov;27(5):699-711
pubmed: 12431845
Eur Child Adolesc Psychiatry. 2004;13 Suppl 1:I7-30
pubmed: 15322953
Eur Child Adolesc Psychiatry. 2004 Oct;13(5):307-14
pubmed: 15490278
Biol Psychiatry. 2005 Jun 1;57(11):1231-8
pubmed: 15949993
Lancet. 2005 Jul 16-22;366(9481):237-48
pubmed: 16023516
Arch Gen Psychiatry. 2005 Nov;62(11):1266-74
pubmed: 16275814
Adv Neurol. 2006;99:99-106
pubmed: 16536355
Semin Pediatr Neurol. 2006 Dec;13(4):231-42
pubmed: 17178353
Cell. 2007 Apr 20;129(2):397-410
pubmed: 17448997
J Child Adolesc Psychopharmacol. 2007 Aug;17(4):393-406
pubmed: 17822336
CNS Spectr. 2008 Dec;13(12):1047-55
pubmed: 19179940
Hum Genet. 2009 Jul;126(1):51-90
pubmed: 19506906
CNS Drugs. 2009;23 Suppl 1:21-31
pubmed: 19621975
J Am Acad Child Adolesc Psychiatry. 2009 Sep;48(9):884-93
pubmed: 19625978
Postgrad Med. 2010 Sep;122(5):78-87
pubmed: 20861591
J Neurosci. 2012 Jan 18;32(3):841-9
pubmed: 22262882
J Am Acad Child Adolesc Psychiatry. 2013 Sep;52(9):921-30
pubmed: 23972694
Behav Brain Res. 2014 Aug 15;270:349-56
pubmed: 24882610
Atten Defic Hyperact Disord. 2015 Mar;7(1):27-38
pubmed: 24942707
J Child Adolesc Psychopharmacol. 2014 Aug;24(6):302-10
pubmed: 24956171
Eur Neuropsychopharmacol. 2014 Dec;24(12):1861-72
pubmed: 25453486
Ann Neurol. 1987 Mar;21(3):307-10
pubmed: 3300518
Drugs. 1986 Apr;31(4):301-36
pubmed: 3519177
JAMA. 1982 Feb 26;247(8):1168-9
pubmed: 6120250
Br J Clin Pharmacol. 1980;10 Suppl 1:25S-32S
pubmed: 6994775
Eur J Pharmacol. 1977 Jan 21;41(2):133-43
pubmed: 832672
Brain Res. 1995 Sep 4;690(2):217-24
pubmed: 8535839
J Am Acad Child Adolesc Psychiatry. 1996 Apr;35(4):409-32
pubmed: 8919704
Eur J Neurosci. 1997 Oct;9(10):2077-85
pubmed: 9421168
J Neurosci. 1998 Apr 1;18(7):2697-708
pubmed: 9502827
J Neurochem. 1998 Jul;71(1):274-80
pubmed: 9648875
Am J Psychiatry. 1998 Oct;155(10):1325-31
pubmed: 9766762